Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Intradigm's RNAi Nanoplex technology helps combat tumour growth

Intradigm : 15 April, 2008  (Company News)
Intradigm has released study results that demonstrate the company's RNAi Nanoplex (NPX) delivery technology platform is capable of effectively delivering small interfering RNAs (siRNAs) targeting both vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF) pathways.
Both pathways have been clinically validated in the treatment of a variety of cancers.

The study data demonstrates that mice treated with Intradigm's proprietary peptide-based, biodegradable polymer (PolyTran) carrying each of VEGF-, VEGFR2- or EGFR-targeted siRNAs experienced significant tumour growth inhibition that was similar to that of mice receiving the study's positive control (VEGF antibody Bevacizumab or EGFR tyrosine kinase inhibitor Erlotinib). In addition, mice in the active siRNA treatment groups demonstrated no apparent toxicity or significant weight loss.

These study findings, which also confirmed the gene-silencing mechanism of action of Intradigm's technology, were presented by Intradigm scientists at the 2008 American Association for Cancer Research (AACR) Annual Meeting in San Diego.

'We are very pleased with these study results as they confirm the gene-silencing mechanism of our RNAi NPX delivery technology, as well as its ability to systemically deliver siRNAs to tumors in a safe and effective manner,' said Mohammad Azab, MD, president and chief executive officer of Intradigm. 'Furthermore, by effectively targeting VEGF, VEGFR2, and EGFR, three established oncology targets, with our siRNAs, we have demonstrated the versatility of the RNAi NPX delivery technology which could be translated into multiple product opportunities for Intradigm's pipeline of RNAi therapeutics.'

The findings support data from several other in vivo models, including xenograft models of different cancers, which have demonstrated the efficacy of the RNAi NPX delivery technology.

Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo